Marcos de Lima
Marcos de Lima is an expert in Hematology at James Cancer Hospital (United States). As of April 2026, ScienceLeadR ranks Marcos de Lima in the top 1% of experts worldwide for Stem Cell Transplantation, Cell Transplantation and Leukemia. Marcos de Lima has authored 602 publications, the most recent in 2025, and is an investigator in 16 clinical trials, 1 of them ongoing. SLR score: 1,878 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Transplantation - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1996 - 2025
Number : 602
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Presence of Clonal Hematopoiesis and Cardiac Events After Allogeneic Stem Cell Transplantation. PMID 40970503 — cells, heart diseases, hematopoiesis, microscopy, electron, scanning transmission, heart, neoplasms, clonal hematopoiesis, stem cells, atrial fibrillation, cell transplantation, stem cell transplantation, mutation, transplantation | J Am Heart Assoc | 2025 | 0 |
| Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis. PMID 40623049 — hematology, hodgkin disease, lymphoma, transplants | Blood | 2025 | 0 |
| Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphoma. PMID 40589093 — cells, creatinine, hematology, lymphoma, b-cell, lymphoma, recycling, kidney, receptors, antigen, receptors, chimeric antigen, risk factors, therapeutics, history, t-lymphocytes, b-lymphocytes, acute kidney injury, receptors, antigen, t-cell | Br J Haematol | 2025 | 0 |
| CIBMTR Registry Data on Inotuzumab Ozogamicin Treatment in Patients with ALL Who Proceeded to Hematopoietic Stem Cell Transplant-A Podcast. PMID 40111710 — registries, cells, precursor cell lymphoblastic leukemia-lymphoma, hepatic veno-occlusive disease, microscopy, electron, scanning transmission, incidence, neoplasms, stem cells, inotuzumab ozogamicin, transplants, therapeutics, hematopoietic stem cells | Target Oncol | 2025 | 0 |
| Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial. PMID 40115173 — cells, lymphoma, follicular, safety, point-of-care systems, hodgkin disease, lymphoma, blood component removal, lymphoma, non-hodgkin, therapeutics, car-t cell | EClinicalMedicine | 2025 | 4 |
Clinical Studies 16
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| CAR T Cells for HIV Infection NCT04648046 — cells, hiv-1, safety, pharmaceutical preparations, cyclophosphamide, acquired immunodeficiency syndrome, immunotherapy, hiv, therapeutics, conditioning, psychological, hiv infections, infections, car-t cell | Phase 1/Phase 2 | Recruiting | 2021 |
LeadR Networks
Main global connection map